Amgen to Acquire Scholar Rock for $792M

Ticker: SRRK · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1727196

Sentiment: bullish

Topics: acquisition, biotech, merger

Related Tickers: AMGN

TL;DR

Amgen buying Scholar Rock for $792M cash, deal expected H2 2025.

AI Summary

Scholar Rock Holding Corp. announced on June 18, 2025, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $3.75 per share in cash, totaling approximately $792 million. This transaction is expected to close in the second half of 2025, subject to customary closing conditions.

Why It Matters

This acquisition by Amgen, a major biotechnology company, could significantly impact the development and commercialization of Scholar Rock's pipeline, particularly its treatments for fibrotic diseases.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.

Key Numbers

Key Players & Entities

FAQ

What is the primary reason for Amgen's acquisition of Scholar Rock?

Amgen is acquiring Scholar Rock to gain access to its pipeline of innovative therapies, particularly for fibrotic diseases, and its novel approach to targeting the TGF-beta superfamily.

What is the expected timeline for the completion of the acquisition?

The transaction is expected to close in the second half of 2025.

What is the total value of the transaction?

The transaction is valued at approximately $792 million in cash.

What is the price per share offered to Scholar Rock stockholders?

Amgen has agreed to acquire Scholar Rock for $3.75 per share in cash.

Are there any specific regulatory hurdles mentioned for the acquisition?

The filing mentions that the transaction is subject to customary closing conditions, which would include regulatory approvals.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding Scholar Rock Holding Corp (SRRK).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing